300642.SHE Tellgen Corp
- Market cap
- CNY 2.46B
- P/E
- 126.2x
- P/B
- 1.79x
- ROE
- 1.9%
- Dividend yield
- 1.17%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300642.SHE undervalued?
Graham numberThe Graham number of Tellgen Corp cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tellgen Corp fundamental analysis
No fundamental analysis for Tellgen Corp yet.
Tellgen Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tellgen Corp
Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; det…
Full company profileTellgen Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tellgen Corp annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 231M | 303M | 365M | 441M | 490M | 655M | 716M | 543M | 437M | 364M | 384M |
| Gross Profit | 186M | 243M | 286M | 346M | 322M | 434M | 407M | 354M | 280M | 253M | 263M |
| Operating Income | 106M | 147M | 165M | 182M | 132M | 181M | 131M | 88.4M | 38.6M | 38.5M | 32.1M |
| EBITDA | 131M | 171M | 198M | 224M | 186M | 246M | 207M | 161M | 98.3M | 59.5M | 45.0M |
| Net Income | 97.8M | 127M | 142M | 157M | 121M | 161M | 125M | 89.4M | 34.5M | 3.59M | 28.0M |
| EPS | 0.80 | 0.85 | 0.87 | 0.97 | 0.74 | 0.98 | 0.77 | 0.55 | 0.21 | 0.02 | 0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 341M | 935M | 1.10B | 1.25B | 1.37B | 1.50B | 1.66B | 1.68B | 1.75B | 2.06B | 2.02B |
| Total Liabilities | 51.9M | 39.3M | 78.7M | 77.8M | 105M | 103M | 184M | 144M | 231M | 576M | 543M |
| Shareholders' Equity | 289M | 896M | 1.02B | 1.17B | 1.27B | 1.39B | 1.47B | 1.53B | 1.51B | 1.43B | 1.44B |
| Cash & Short-term Investments | 116M | 608M | 505M | 634M | 557M | 458M | 504M | 492M | 490M | 386M | 284M |
| Total Debt | 15.4M | - | 26.5M | 17.5M | 16.4M | 16.9M | 21.9M | 6.02M | 97.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 98.4M | 106M | 161M | 175M | 96.8M | 82.6M | 165M | 126M | 165M | 143M | - |
| Capital Expenditure | 64.9M | 75.4M | 145M | 100M | 79.5M | 114M | 66.9M | 101M | 86.5M | 67.3M | 61.5M |
| Free Cash Flow | 33.5M | 30.6M | 16.8M | 74.7M | 17.4M | -31.2M | 97.8M | 25.1M | 78.1M | 75.9M | 104M |
| Ratios | |||||||||||
| ROE | 33.9% | 14.2% | 13.8% | 13.4% | 9.5% | 11.6% | 8.5% | 5.8% | 2.3% | 0.3% | 1.9% |
| ROA | 28.7% | 13.6% | 12.8% | 12.6% | 8.8% | 10.7% | 7.5% | 5.3% | 2.0% | 0.2% | 1.4% |
| Net Profit Margin | 42.3% | 41.9% | 38.8% | 35.6% | 24.6% | 24.6% | 17.4% | 16.5% | 7.9% | 1.0% | 7.3% |
| Debt to Equity | 0.05x | - | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tellgen Corp dividends
- Dividend yield
- 1.17%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 803.7%
- Ex-dividend date
- Sep 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 28.8M | 0.18 | 803.7% |
| 2024 | CNY 25.6M | 0.16 | 74.2% |
| 2023 | CNY 33.1M | 0.20 | 37.1% |
| 2022 | CNY 40.7M | 0.25 | 32.6% |
| 2021 | CNY 36.4M | 0.22 | 22.6% |
| 2020 | CNY 36.3M | 0.22 | 30.1% |
| 2019 | CNY 27.3M | 0.17 | 17.4% |
| 2018 | CNY 24.2M | 0.15 | 17.1% |
| 2017 | CNY 18.0M | 0.12 | 14.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.8:1 on Sep 16, 2021.
Who owns Tellgen Corp
- Insiders 34.97%
- Institutions 7.91%
- Public & others 57.13%
- Shares outstanding 162M
- Free float 112M
Tellgen Corp company profile
- Company name
- Tellgen Corp
- Ticker
- 300642.SHE
- ISIN
- CNE100002P42
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 683
- Fiscal year end
- December
- Address
- No. 412 Huiqing Road, Shanghai, China, 201201
- Phone
- 86 21 5086 2711
- Website
- tellgen.com
About Tellgen Corp
Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; detection products for invasive fungal diseases. The company was founded in 2003 and is based in Shanghai, China.
Tellgen Corp management
6- Mr. Jian Er YaoNon-Independent Chairman of Board & GM · born 1970
- Mr. Songtao LiFinancial Manager & Accounting Supervisor · born 1976
- Mr. En Huan YangDeputy GM & Non-Independent Director · born 1982
- Mr. Chen GangDeputy General Manager · born 1966
- Mr. Xiaoqing WangDeputy GM, Secretary of Board of Directors, Director of GM's Office & Non-Independent Director · born 1979
- Mr. Ye ShengDirector of R&D and Deputy GM · born 1981